Follicular lymphoma: 2020 update on diagnosis and management
A Freedman, E Jacobsen - American journal of hematology, 2020 - Wiley Online Library
Disease overview Follicular lymphoma (FL) is generally an indolent B cell
lymphoproliferative disorder of transformed follicular center B cells. Follicular lymphoma is …
lymphoproliferative disorder of transformed follicular center B cells. Follicular lymphoma is …
Follicular lymphoma: evolving therapeutic strategies
BS Kahl, DT Yang - Blood, The Journal of the American Society …, 2016 - ashpublications.org
Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma in the
Western hemisphere. After decades of stagnation, the natural history of FL appears to have …
Western hemisphere. After decades of stagnation, the natural history of FL appears to have …
Follicular lymphoma: 2023 update on diagnosis and management
E Jacobsen - American Journal of Hematology, 2022 - Wiley Online Library
Abstract Disease Overview Follicular lymphoma (FL) is generally an indolent B cell
lymphoproliferative disorder of transformed follicular center B cells. FL is characterized by …
lymphoproliferative disorder of transformed follicular center B cells. FL is characterized by …
Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009
Abstract The European Group for Blood and Marrow Transplantation regularly publishes
special reports on the current practice of haematopoietic SCT for haematological diseases …
special reports on the current practice of haematopoietic SCT for haematological diseases …
Phase III trial of consolidation therapy with yttrium-90–ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma
F Morschhauser, J Radford, A Van Hoof… - Journal of Clinical …, 2008 - ascopubs.org
Purpose We conducted an international, randomized, phase III trial to evaluate the efficacy
and safety of consolidation with yttrium-90 (90Y)–ibritumomab tiuxetan in patients with …
and safety of consolidation with yttrium-90 (90Y)–ibritumomab tiuxetan in patients with …
Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study
G Salles, N Mounier, S de Guibert… - Blood, The Journal …, 2008 - ashpublications.org
The FL2000 study was undertaken to evaluate the combination of the anti-CD20 monoclonal
antibody rituximab with chemotherapy plus interferon in the first-line treatment of follicular …
antibody rituximab with chemotherapy plus interferon in the first-line treatment of follicular …
Follicular lymphoma: 2018 update on diagnosis and management
A Freedman - American journal of hematology, 2018 - Wiley Online Library
Disease overview Follicular lymphoma is generally an indolent B cell lymphoproliferative
disorder of transformed follicular center B cells. Follicular lymphoma (FL) is characterized by …
disorder of transformed follicular center B cells. Follicular lymphoma (FL) is characterized by …
[HTML][HTML] ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic …
M Ghielmini, U Vitolo, E Kimby, S Montoto, J Walewski… - Annals of …, 2013 - Elsevier
To complete the existing treatment guidelines for all tumor types, ESMO organizes
consensus conferences to better clarify open issues in each disease. In this setting, a …
consensus conferences to better clarify open issues in each disease. In this setting, a …
Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98
G Martinelli, SF Hsu Schmitz, U Utiger… - Journal of clinical …, 2010 - ascopubs.org
Purpose We report the long-term results of a randomized clinical trial comparing induction
therapy with once per week for 4 weeks single-agent rituximab alone versus induction …
therapy with once per week for 4 weeks single-agent rituximab alone versus induction …
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular …
M Ladetto, F De Marco, F Benedetti… - Blood, The Journal …, 2008 - ashpublications.org
In this randomized multicenter study of 136 patients, 6 courses of CHOP (cyclo-
phosphamide/doxorubicin/vincristine/prednisone) followed by rituximab (CHOP-R) were …
phosphamide/doxorubicin/vincristine/prednisone) followed by rituximab (CHOP-R) were …